People: CytRx Corp (CYTR.PH)

Summary

Name	Age	Since	Current Position
Max Link	72	2002	Independent Chairman of the Board
Steven Kriegsman	71	2002	President, Chief Executive Officer, Director
Marvin Selter	85	2004	Independent Vice Chairman of the Board
John Caloz	61	2009	Chief Financial Officer
Daniel Levitt	65	2013	Executive Vice President, Chief Medical Officer
Douglas Wieland	53	2008	Senior Vice President - Drug Development
Benjamin Levin	36	2004	Vice President - Legal Affairs, General Counsel, Corporate Secretary
David Haen	34	2007	Vice President - Business Development
Louis Ignarro	71	2002	Independent Director
Joseph Rubinfeld	80	2002	Independent Director
Richard Wennekamp	70	2003	Independent Director
Thomas Wagner			IR Contact

» Insider Trading

Biographies

Name	Description
Max Link	Dr. Max E. Link, Ph.D., is Independent Chairman of the Board of CytRx Corporation . He has been a director since 1996. Dr. Link has been retired from business since 2003. From March 2002 until its acquisition by Zimmer Holdings, Dr. Link served as Chairman and CEO of Centerpulse, Ltd. From May 1993 to June 1994, Dr. Link served as the Chief Executive Officer of Corange Ltd. (the holding company for Boehringer Mannheim Therapeutics, Boehringer Mannheim Diagnostics and DePuy International). From 1992 to 1993, Dr. Link was Chairman of Sandoz Pharma, Ltd. From 1987 to 1992, Dr. Link was the Chief Executive Officer of Sandoz Pharma and a member of the Executive Board of Sandoz, Ltd., Basel. Prior to 1987, Dr. Link served in various capacities with the United States operations of Sandoz, including President and Chief Executive Officer. Dr. Link currently serves as a director of Alexion Pharmaceuticals, Inc., Celsion Corporation, Inc. and Discovery Laboratories, Inc., and has previously served on the Boards of Directors of Cell Therapeutics, Inc., Columbia Laboratories, Inc., Human Genome Sciences, Inc. and Protein Design Laboratories.
Steven Kriegsman	Mr. Steven A. Kriegsman is President, Chief Executive Officer and Director of CytRx Corporation. He also serves as a director of Galena Biopharma and is Chairman of its Compensation and Transactions Committees. He previously served as Director and Chairman of Global Genomics from June 2000 until 2002. Mr. Kriegsman is an inactive Chairman and Founder of Kriegsman Capital Group LLC, a financial advisory firm specializing in the development of alternative sources of equity capital for emerging growth companies in the healthcare industry. During his career, he has advised such companies as SuperGen Inc., Closure Medical Corporation, Novoste Corporation, Miravant Medical Technologies, and Maxim Pharmaceuticals. In the past five years, Mr. Kriegsman has also served on the Board of Directors of Bradley Pharmaceuticals, Inc. and Hythiam, Inc. Mr. Kriegsman has a B.S. degree with honors from New York University in Accounting and completed the Executive Program in Mergers and Acquisitions at New York University, The Management Institute. Mr. Kriegsman is a graduate of the Stanford Law School Directors’ College. Mr. Kriegsman was formerly a Certified Public Accountant with KPMG in New York City. In February 2006, Mr. Kriegsman received the Corporate Philanthropist of the Year Award from the Greater Los Angeles Chapter of the ALS Association and in October 2006, he received the Lou Gehrig Memorial Corporate Award from the Muscular Dystrophy Association. Mr. Kriegsman has been a guest speaker and lecturer at various universities including California Institute of Technology (Caltech), Brown University, and New York University. Mr. Kriegsman has been active in various charitable organizations including the Biotechnology Industry Organization, the California Health Institute, the ALS Association, the Los Angeles Venture Association, the Southern California Biomedical Council, the American Association of Dance Companies and the Palisades-Malibu YMCA.
Marvin Selter	Mr. Marvin R. Selter is Independent Vice Chairman of the Board of CytRx Corporation. He has been a director since October 2003. He has been President and Chief Executive Officer of CMS, Inc. since he founded that firm in 1968. CMS, Inc. is a national management consulting firm. In 1972, Mr. Selter originated theconcept of employee leasing. He served as a member of the Business Tax Advisory Committee—City of Los Angeles, Small Business Board—State of California and the Small Business Advisory Commission—State of California. Mr. Selter also serves on the Valley Economic Development Center as past Chairman and Audit Committee Chairman, the Board of Valley Industry and Commerce Association as past Chairman, the Advisory Board of the San Fernando Economic Alliance and the California State University—Northridge as Past Chairman of the Economic Research Center and President of the Olive View UCLA Medical Center Foundation. He has served, and continues to serve, as a member of boards of directors of various hospitals, universities, private medical companies and other organizations. Mr. Selter attended Rutgers—The State University, majoring in Accounting and Business Administration. He was an LPA having served as Controller, Financial Vice President and Treasurer at distribution, manufacturing and service firms. He has lectured on finance, corporate structure and budgeting for the American Management Association and other professional teaching associations.
John Caloz	Mr. John Y. Caloz is Chief Financial Office of CytRx Corporation. He joined the company in October 2007 as Chief Accounting Officer. In January of 2009 Mr. Caloz was named Chief Financial Officer. He has a history of providing senior financial leadership in the life sciences sector, as Chief Financial Officer of Occulogix, Inc, a NASDAQ listed, a medical therapy company. Prior to that, Mr. Caloz served as Chief Financial Officer of IRIS International Inc., a Chatsworth, CA based medical device manufacturer. He served as Chief Financial Officer of San Francisco-based Synarc, Inc., a medical imaging company, and from 1993 to 1999 he was Senior Vice President, Finance and Chief Financial Officer of Phoenix International Life Sciences Inc. of Montreal, Canada, which was acquired by MDS Inc. in 1999. Mr. Caloz was a partner at Rooney, Greig, Whitrod, Filion & Associates of Saint Laurent, Quebec, Canada, a firm of Chartered Accountants specializing in research and development and high tech companies, from 1983 to 1993. Mr. Caloz, a Chartered Accountant, holds a degree in Accounting from York University, Toronto, Canada.
Daniel Levitt	Dr. Daniel Levitt, M.D., Ph.D., is Executive Vice President, Chief Medical Officer of CytRx Corp. Dr. Levitt brings more than 24 years of senior management experience, having spearheaded numerous drug development programs to commercialization at biotechnology and pharmaceutical companies. Prior to joining CytRx, Dr. Levitt served from January 2007 to February 2009 as Executive Vice President, Research and Development at Cerimon Pharmaceuticals, Inc. Prior to that, from August 2003 to April 2006, he was Chief Medical Officer and Head of Clinical and Regulatory Affairs at Dynavax Technologies Corporation, managing clinical trials for four programs and overseeing multi-country regulatory strategies. From August 2002 to July 2003, Dr. Levitt was Chief Operating Officer and Head of Research and Development at Affymax, Inc., and prior to that he spent six years at Protein Design Labs, Inc., completing his tenure as that firm’s President and Head of Research and Development. Dr. Levitt’s past experience includes a position as Head of Drug Development at Geron Corporation, and Head of the Cytokine Development Unit and Global Clinical Oncology at Sandoz Pharmaceuticals Ltd., and as Director, Clinical Oncology and Immunology at Hoffmann-LaRoche, Inc. Dr. Levitt graduated Magna Cum Laude and Phi Beta Kappa with a Bachelor of Arts degree from Brandeis University. He earned both his M.D. and his Ph.D. in Biology from the University of Chicago, Pritzker School of Medicine. Dr. Levitt has received 10 research awards and authored or co-authored nearly 200 papers and abstracts.
Douglas Wieland	Dr. Douglas Scott Wieland, Ph.D., is Senior Vice President - Drug Development of CytRx Corporation. He joined CytRx in 2005 as the Vice President, Clinical and Regulatory Affairs and was promoted to the position of Senior Vice President, Drug Development in December 2008. Prior to that, he served in senior level positions in the areas of Drug Development, Clinical and Regulatory Affairs at various biotech firms. He spent five years at NeoTherapeutics, Inc. serving as the Director of Product Development and was later promoted to Vice President of Product Development. From 1990 to 1997, he served as Director of Regulatory Affairs at CoCensys, Inc. Dr. Wieland has a Ph.D. in Biopsychology and an M.A. in Psychology from the University of Arizona. He has an MBA from Webster University. Dr. Wieland received his B.S. in Physiological Psychology from the University of California, Santa Barbara.
Benjamin Levin	Mr. Benjamin S. Levin is the Vice President - Legal Affairs, General Counsel, Corporate Secretary of CytRx Corporation. From November 1999 to June 2004, Mr. Levin was an associate in the transactions department of the Los Angeles office of O’Melveny & Myers LLP. Mr. Levin received his S.B. in Economics from the Massachusetts Institute of Technology, and a J.D. from Stanford Law School.
David Haen	Mr. David J. Haen is Vice President – Business Development of Cytrx Corporation. He joined CytRx in October 2003 as Director of Business Development and was promoted to Vice President of Business Development in December 2007. From 1999 to 2003, Mr. Haen worked as an associate for Kriegsman Capital Group LLC, a financial advisory firm focused on emerging companies in the life sciences field. Mr. Haen received a B.A. in Communications and Business from Loyola Marymount University.
Louis Ignarro	Dr. Louis J. Ignarro, Ph.D., is Independent Director of CytRx Corporation. He previously served as a director of Global Genomics since November 20, 2000. Dr. Ignarro serves as the Jerome J. Belzer, M.D. Distinguished Professor of Pharmacology in the Department of Molecular and Medical Pharmacology at the UCLA School of Medicine. Dr. Ignarro has been at the UCLA School of Medicine since 1985 as a professor, acting chairman and assistant dean. Dr. Ignarro received the Nobel Prize for Medicine in 1998. Dr. Ignarro received a B.S. in pharmacy from Columbia University and his Ph.D. in Pharmacology from the University of Minnesota. Dr. Ignarro is a Nobel Laureate and an esteemed medical researcher whose experience enables him to offer importance scientific guidance to Board of Directors.
Joseph Rubinfeld	Dr. Joseph Rubinfeld, Ph.D., is a Independent Director of CytRx Corporation. He co-founded SuperGen, Inc. in 1991 and has served as its Chief Executive Officer and President and as a director since its inception until December 31, 2003. He resigned as Chairman Emeritus of SuperGen, Inc. on February 8, 2005. Dr. Rubinfeld was also Chief Scientific Officer of SuperGen from 1991 until September 1997. Dr. Rubinfeld is also a founder of JJ Pharma. Dr. Rubinfeld was one of the four initial founders of Amgen, Inc. in 1980 and served as a Vice President and its Chief of Operations until 1983. From 1987 until 1990, Dr. Rubinfeld was a Senior Director at Cetus Corporation and from 1968 to 1980, Dr. Rubinfeld was employed at Bristol-Myers Company, International Division in a variety of positions. Dr. Rubinfeld received a B.S. degree in chemistry from C.C.N.Y. and an M.A. and Ph.D. in chemistry from Columbia University.
Richard Wennekamp	Mr. Richard L. Wennekamp is Independent Director of CytRx Corporation. He retired from Community Bank in June 2008 where he was the Senior Vice President-Credit Administration since October 2002. From September 1980 to July 2002, Mr. Wennekamp was an executive officer of Bank of America Corporation, holding various positions, including Managing Director-Credit Product Executive for the last four years of his 22-year term with the bank. From 1977 through 1980, Mr. Wennekamp was a Special Assistant to former President of the United States, Gerald R. Ford, and the Executive Director of the Ford Transition Office. Prior thereto, he served as Staff Assistant to the President of the United States for one year, and as the Special Assistant to the Assistant Secretary of Commerce of the U.S.
Thomas Wagner

Basic Compensation

Name	Fiscal Year Total
Max Link	--
Steven Kriegsman	1,518,700
Marvin Selter	--
John Caloz	546,000
Daniel Levitt	786,900
Douglas Wieland	536,000
Benjamin Levin	546,000
David Haen	--
Louis Ignarro	--
Joseph Rubinfeld	--
Richard Wennekamp	--
Thomas Wagner	--

As Of 30 Dec 2012

Options Compensation

Name	Options	Value
Max Link	0	0
Steven Kriegsman	864,000	508,000
Marvin Selter	0	0
John Caloz	0	0
Daniel Levitt	0	0
Douglas Wieland	0	0
Benjamin Levin	310,000	36,000
David Haen	0	0
Louis Ignarro	0	0
Joseph Rubinfeld	0	0
Richard Wennekamp	0	0
Thomas Wagner	0	0

Insider Trading

Name	Shares Traded	Price
PATTERSON SCOTT BRADFORD	4,083	$2.70
PATTERSON SCOTT BRADFORD	8,420	$2.57
PATTERSON SCOTT BRADFORD	3,980	$2.61
PATTERSON SCOTT BRADFORD	24,100	$2.58
PATTERSON SCOTT BRADFORD	3,000	$2.56
PATTERSON SCOTT BRADFORD	360	$2.52
PATTERSON SCOTT BRADFORD	55,000	$2.67
LEVITT DANIEL J	100,000	$0.00
PATTERSON SCOTT BRADFORD	115,000	$2.51
PATTERSON SCOTT BRADFORD	65,000	$2.51
PATTERSON SCOTT BRADFORD	1,200,000	$2.50
PATTERSON SCOTT BRADFORD	16,000	$4.90
PATTERSON SCOTT BRADFORD	15,824	$5.23
PATTERSON SCOTT BRADFORD	13,000	$5.32
PATTERSON SCOTT BRADFORD	17,835	$5.16
PATTERSON SCOTT BRADFORD	5,334	$4.74
PATTERSON SCOTT BRADFORD	4,293	$4.61
PATTERSON SCOTT BRADFORD	7,283	$4.65
PATTERSON SCOTT BRADFORD	9,210	$4.48
PATTERSON SCOTT BRADFORD	4,621	$4.25
PATTERSON SCOTT BRADFORD	3,558	$3.89
PATTERSON SCOTT BRADFORD	10,976	$3.83
PATTERSON SCOTT BRADFORD	14,176	$3.88
PATTERSON SCOTT BRADFORD	5,594	$3.80
PATTERSON SCOTT BRADFORD	23,399	$3.80

» Full list on Insider Trading

People: CytRx Corp (CYTR.PH)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: